DarioHealth

DarioHealth FCF/Debt

The Free Cash Flow to Debt Ratio of DarioHealth (DRIO) as of Nov 16, 2026 is -82.16 %. In the previous year, Free Cash Flow to Debt Ratio was -128.18 % — a change of -35.91% (higher).

FCF/Debt

-82.16 %

YoY

-35.91%

Last updated:

Free Cash Flow to Debt Ratio of DarioHealth is 2025 -82.16 % . Free Cash Flow to Debt Ratio of DarioHealth was 2024 -128.18 % . It decreases by -35.91% higher compared to the previous year.

The DarioHealth FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2015
-270.98 USD
Jan 1, 2019
-2,049.61 USD
Jan 1, 2020
-3,356.02 USD
Jan 1, 2021
-17,655.05 USD
Jan 1, 2022
-172.63 USD
Jan 1, 2023
-104.81 USD
Jan 1, 2024
-128.18 USD
Jan 1, 2025
-82.16 USD
The DarioHealth FCF/Debt history
YEARFCF/DebtYoY
-82.16 %-35.91%
-128.18 %+22.29%
-104.81 %-39.28%
-172.63 %-99.02%
-17,655.05 %+426.07%
-3,356.02 %+63.74%
-2,049.61 %+656.37%
-270.98 %-18.30%
-331.66 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

DarioHealth Stock analysis

What does DarioHealth do? DarioHealth Corp. generates revenue through its digital therapeutics products, including the Dario Blood Glucose Monitoring System and the Dario Smart Diabetes Management Solution, sold via smartphone applications. These products are available on online marketplaces such as Amazon, Walmart, Best Buy, Google, and Apple app stores, targeting consumers directly. The DarioEngage platform offers real-time connectivity between users and caregivers, while Dario Intelligence provides analytics tools for healthcare providers to enhance treatment predictability. The company focuses on delivering integrated digital interventions at the intersection of life sciences, behavioral science, and software technology. DarioHealth's primary buyers are consumers seeking diabetes management solutions through direct-to-consumer channels. The company leverages partnerships with major retailers and app stores to reach its target audience, emphasizing user-centered design and evidence-based reporting. Its services are designed to support both individual users and healthcare providers through data-driven insights and engagement tools. The Dario Blood Glucose Monitoring System and Dario Smart Diabetes Management Solution form the core of DarioHealth's product offerings, delivered through mobile applications. These solutions integrate behavioral science with software technology to provide continuous support for diabetes management. The DarioEngage platform facilitates two-way communication, and Dario Intelligence assists healthcare providers in treatment planning and disease prediction, creating a comprehensive ecosystem for diabetes care. DarioHealth is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DarioHealth stock

Free Cash Flow to Debt Ratio of DarioHealth is -82.16 % in 2025.

Free Cash Flow to Debt Ratio of DarioHealth changed from -128.18 % to -82.16 %, representing a -35.91% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio DarioHealth since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's DarioHealth with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — DarioHealth

All Key Metrics — DarioHealth